Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

IK-595 first cohort treated and cleared safety evaluation window

January 25, 2024

First Patient Enrolled in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

January 25, 2024

NGC-Cap Program expanded into Advanced or Metastatic Breast Cancer

January 25, 2024

Last Patient Enrolled in Ph 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

January 18, 2024

Enrollment opens for Ph 1b/2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer

January 18, 2024

First Dose Cohort in Ph 1 Trial of BP1002 to Treat R/R Lymphoma and R/R CLL Patients completed

January 18, 2024

First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer

January 18, 2024

Global Ph 3 studies started for bomedemstat, nemtabrutinib, MK-2870, and MK-5684

January 10, 2024

Patients enrolled into the 3rd Dosing Cohort of Ph 1/2 Study of ONCT-534 in R/R Metastatic CRPC

January 10, 2024

First Patient Dosed in Ph 1 Trial of ST-001 in T cell NHL

January 10, 2024

23ME-00610 Ph 1/2a trial in advanced neuroendocrine and ovarian cancer patient cohorts expanded

January 10, 2024

First Patient Dosed in Ph 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

January 10, 2024

Status of Ph 1/2 Study of ONCT-808 in Patients with R/R Aggressive B-cell Lymphoma announced

January 10, 2024

Two Ph 3 Trials of Datopotamab Deruxtecan + Imfinzi Initiated in Patients Across Two Breast Cancer Subtypes

January 10, 2024

Dose Selection announced in THIO-101 Ph 2 Trial for NSCLC

January 10, 2024

Investigator-initiated Ph 1/2 Trial of Seclidemstat + Azacitidine to Treat Heme Cancers Resumes Patient Enrollment

January 10, 2024

Enrollment Completed in Ph 3 Bridging Study of Uproleselan in Chinese Patients with R/R AML

January 10, 2024

Ph 1b portion of Ph 1b/2 lanraplenib study in patients with R/R FLT3-mutated AML completed

January 10, 2024

First Patient Dosed in Trial Evaluating Efti and BAVENCIO in Metastatic Urothelial Cancer

January 10, 2024

First Patient Dosed In Ph1/2 Trial Of TNG348 In Patients With BRCA1/2-Mutant and Other HRD+ Cancers

January 10, 2024

Ph 3 INTerpath-002 Study of V940 (mRNA-4157) – KEYTRUDA combination for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC

December 19, 2023

First Patient Dosed in Ph 2b Trial of Samuraciclib + Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer

December 19, 2023

First Patients Enrolled in 60 mg Dose Cohort in Ph 2a Trial of SLS009 in AML

December 19, 2023

Enrollment of Ph 2/3 Trial of Fruquintinib + Sintilimab for Advanced RCC in China completed

December 19, 2023

CB-010 Ph 3 Trial Initiation Expected by YE 2024

December 19, 2023
Page1 … Page13 Page14 Page15 Page16 Page17 … Page23

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.